Related Experiment Video
Updated: Jan 25, 2026

A Novel Murine Model of Arteriovenous Fistula Failure: The Surgical Procedure in Detail
Published on: February 3, 2016
Effects of Arteriovenous Fistula Ligation on Cardiac Structure and Function in Kidney Transplant Recipients
Nitesh N Rao1,2,3, Michael B Stokes4, Adil Rajwani4,5
1Adelaide Medical School, University of Adelaide, Australia (N.N.R., S.U., R.P.C., S.P.M., M.I.W., P.T.C.).
Insights
Ligating arteriovenous fistulas (AVFs) after kidney transplant significantly reduces left ventricular mass. This intervention offers a potential strategy to improve cardiovascular health in transplant recipients.
Area of Science:
- Cardiology
- Nephrology
- Transplantation Medicine
Background:
- High cardiovascular morbidity and mortality persist in kidney transplant recipients.
- Patent arteriovenous fistulas (AVFs) may contribute to maladaptive cardiovascular remodeling post-transplant.
- The potential for AVF ligation to reverse this remodeling is unknown.
Purpose of the Study:
- To evaluate the effect of AVF ligation on cardiac structure and function in stable kidney transplant recipients.
- To determine if AVF ligation can reverse maladaptive cardiovascular remodeling.
Main Methods:
- A randomized controlled trial involving kidney transplant recipients with stable graft function (>12 months post-transplant).
- Participants were randomized to AVF ligation or no intervention.
- Cardiac magnetic resonance imaging was used at baseline and 6 months to assess left ventricular (LV) mass, volumes, atrial areas, ejection fraction, NT-proBNP, cardiac output, and brachial flows.
Main Results:
- AVF ligation significantly reduced LV mass by 22.1 g compared to a small increase in the control group (P<0.001).
- Significant decreases were observed in LV volumes, cardiac output, atrial volumes, and NT-proBNP levels post-ligation (P<0.01).
- No significant changes in LV ejection fraction or pulmonary artery velocity were noted; no complications or changes in renal function/blood pressure were observed.
Conclusions:
- Elective ligation of a patent AVF in stable kidney transplant recipients leads to a clinically significant reduction in left ventricular myocardial mass.
- AVF ligation is a safe procedure with no adverse effects on renal function or blood pressure.
- This study provides evidence for AVF ligation as a therapeutic strategy to mitigate cardiovascular remodeling in kidney transplant patients.
Background:
Cardiovascular morbidity and mortality remain high in recipients of a kidney transplant. The persistence of a patent arteriovenous fistula (AVF) after transplantation may contribute to ongoing maladaptive cardiovascular remodeling. The ability to reverse this maladaptive remodeling by ligation of this AVF is unknown. We conducted the first randomized controlled trial to evaluate the effect of AVF ligation on cardiac structure and function in stable kidney transplant recipients.
Methods:
In this randomized controlled trial, kidney transplant recipients (>12 months after transplantation with stable graft function) were randomized to AVF ligation or no intervention. All participants underwent cardiac magnetic resonance imaging at baseline and at 6 months. The primary outcome was the change in left ventricular (LV) mass. Secondary outcomes included changes in LV volumes, left and right atrial areas, LV ejection fraction, NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, cardiac output/index, brachial flows (ipsilateral to AVF), and pulmonary artery velocity.
Results:
A total of 93 patients were screened, of whom 64 met the inclusion criteria and were randomized to the AVF ligation (n=33) or control (n=31) group. Fifty-four participants completed the study: 27 in the AVF ligation group and 27 in the control group. On the second cardiac magnetic resonance scan, a mean decrease of 22.1 g (95% CI, 15.0-29.1) was observed in LV mass in the AVF ligation group compared with a small increase of 1.2 g (95% CI, -4.8 to 7.2) in the control group ( P<0.001). Significant decreases in LV end-diastolic volumes, LV end-systolic volumes, cardiac output, cardiac index, atrial volumes, and NT-proBNP were also seen in the AVF closure group ( P<0.01). No significant changes were observed in LV ejection fraction ( P=0.93) and pulmonary artery velocity ( P=0.07). No significant complications were noted after AVF ligation. No changes in estimated glomerular filtration rate or systolic and diastolic blood pressures were observed between cardiac magnetic resonance scans.
Conclusions:
Elective ligation of patent AVF in adults with stable kidney transplant function resulted in clinically significant reduction of LV myocardial mass.
Clinical Trial Registration:
Australian and New Zealand Clinical Trials Registry URL: https://www.anzctr.org.au . Unique Identifier: ACTRN12613001302741.
Related Concept Videos
Kidney Structure
Kidney Transplant I: Introduction
Structural Protein Function
Collagen, the most abundant protein in mammals, is found throughout the body. In connective tissue, such as skin, ligaments, and tendons, it provides tensile strength and elasticity. In bones and teeth, it mineralizes to...
Structure of Cardiac Muscles
Compared to skeletal muscles, cardiac muscle cells are small and mostly have a single nucleus. Additionally, they are usually...
Kidney Transplant II: Surgical Procedure
Fruit Development, Structure, and Function

